Open AccessProstanoid receptors (version 2020.4) in the IUPHAR/BPS Guide to Pharmacology Database
Author(s) -
Richard M. Breyer,
Lucie H. Clapp,
Robert A. Coleman,
Mark A. Giembycz,
Ákos Heinemann,
Rebecca Hills,
Robert L. Jones,
Shuh Narumiya,
Xavier Norel,
Roy Pettipher,
Yukihiko Sugimoto,
Mohib Uddin,
David F. Woodward,
Chengcan Yao
Publication year - 2020
Publication title -
iuphar/bps guide to pharmacology cite
Language(s) - English
Resource type - Journals
ISSN - 2633-1020
DOI - 10.2218/gtopdb/f58/2020.4
Subject(s) - prostanoid , prostacyclin , receptor , thromboxane a2 , thromboxane receptor , pharmacology , thromboxane , chemistry , medicine , platelet , biochemistry
Prostanoid receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Prostanoid Receptors [661]) are activated by the endogenous ligands prostaglandins PGD2, PGE1, PGE2 , PGF2α, PGH2, prostacyclin [PGI2] and thromboxane A2. Differences and similarities between human and rodent prostanoid receptor orthologues, and their specific roles in pathophysiologic conditions are reviewed in [423]. Measurement of the potency of PGI2 and thromboxane A2 is hampered by their instability in physiological salt solution; they are often replaced by cicaprost and U46619, respectively, in receptor characterization studies.